Peroxisome Proliferator-Activated Receptor-γ Activation Inhibits Tumor Metastasis by Antagonizing Smad3-Mediated Epithelial-Mesenchymal Transition
Ajaya Kumar Reka, Himabindu Kurapati, Venkata R. Narala, Guido Bommer, Jun Chen, Theodore J. Standiford, and Venkateshwar G. Keshamouni

Combined Treatment with Silibinin and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Overcomes Drug Resistance Caused by T790M Mutation
Jin Kyung Rho, Yun Jung Choi, Byung-Suk Jeon, Su Jin Choi, Gi Jeong Cheon, Sang-Keun Woo, Hye-Ryoun Kim, Cheol Hyeon Kim, Chang-Min Choi, and Ja Cheol Lee

Antiangiogenic Activity of a Neutralizing Human Single-Chain Antibody Fragment against Fibroblast Growth Factor Receptor 1
Roberto Ronca, Patrizia Benzoni, Daria Leali, Chiara Urbiniati, Mirella Belleri, Michela Corsini, Patrizia Alessi, Daniela Coltrini, Stefano Calza, Marco Presta, and Patrizia Dell’Era

MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition
Rakesh K. Srivastava, Razelle Kurzrock, and Sharmila Shankar

Chemoprevention of Chemically Induced Skin Tumorigenesis by Ligand Activation of Peroxisome Proliferator–Activated Receptor-β/δ and Inhibition of Cyclooxygenase 2
Bokai Zhu, Robert Bai, Mary J. Kennett, Boo-Hyon Kang, Frank J. Gonzalez, and Jeffrey M. Peters

Combination of Vorinostat and Flavopiridol Is Selectively Cytotoxic to Multidrug-Resistant Neuroblastoma Cell Lines with Mutant TP53
Jen-Ming Huang, Michael A. Sheard, Lingyun Ji, Richard Sposto, and Nino Keshelava

Inhibition of Constitutive Activation of STAT3 by Curcubitacin-I (JSI-124) Sensitized Human B-Leukemia Cells to Apoptosis
Ganchimeg Ishidorj, James B. Johnston, and Spencer B. Gibson

Cytochrome P450 1B1 Gene Polymorphisms as Predictors of Anticancer Drug Activity: Studies with In vitro Models
Audrey Laroche-Clary, Valérie Le Morvan, Takao Yamori, and Jacques Robert

A Synergistic Interaction between Lapatinib and Chemotherapy Agents in a Panel of Cell Lines Is Due to the Inhibition of the Efflux Pump BCRP
Jackie Perry, Essam Ghazaly, Christiana Kitromilidou, Eva H. McGrowder, Simon Joel, and Thomas Powles

Rh–Raf-1 Interaction Disruptor RRD-251 Induces Apoptosis in Metastatic Melanoma Cells and Synergizes with Dacarbazine
Sandeep Singh, Rebecca Davis, Vignesh Alamanda, Roberta Pireddu, Daniel Pernazza, Said Sebti, Nicholas Lawrence, and Srikumar Chellappan

Cyclin G–Associated Kinase Is Necessary for Osteosarcoma Cell Proliferation and Receptor Trafficking
Michiro Susa, Edwin Choy, Xianzhe Liu, Joseph Schwab, Francis J. Hornick, Henry Mankin, and Zhenfeng Duan

Identification of Predictive Markers of Response to the MEKfs1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer
John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafico, Todd M. Pitts, M. Pia Morelli, Heather M. Selby, Maria I. Kachaeva, Sara A. Flanigan, Gillian N. Kulkowski, Stephen Leong, John J. Arcaroli, Wells A. Messersmith, and S. Gail Eckhardt
Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells
Hsin-Yi Tseng, Chen Chen Jiang, Amanda Croft, Kwang Hong Tay, Rick Francis Thorne, Fan Yang, Hao Liu, Peter Hersey, and Xu Dong Zhang

Nakiterpiosin Targets Tubulin and Triggers Mitotic Catastrophe in Human Cancer Cells
Jen-Hsuan Wei and Joachim Seemann

AZ960, a Novel Jak2 Inhibitor, Induces Growth Arrest and Apoptosis in Adult T-Cell Leukemia Cells
Jing Yang, Takayuki Ikezoe, Chie Nishioka, Mutsuo Furihata, and Akihito Yokoyama

Specific Alterations of MicroRNA Transcriptome and Global Network Structure in Colorectal Carcinoma after Cetuximab Treatment
Marco Ragusa, Alessandra Majorana, Luisa Statello, Marco Maugeri, Loredana Salito, Davide Barbagallo, Maria Rosa Guglielmino, Laura R. Duro, Rosario Angelica, Rosario Caltabiano, Antonio Biondi, Maria Di Vita, Giuseppe Privitera, Marina Scalia, Alessandro Cappellani, Enrico Vasquez, Salvatore Lanzafame, Francesco Basile, Cinzia Di Pietro, and Michele Purrello

Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer
Apostolia-Maria Tsimberidou, Wallace Akerley, Matthias C. Schabel, David S. Hong, Cynthia Uehara, Anil Chhabra, Terri Warren, Gary G. Mather, Brent A. Evans, Deane P. Woodland, Edward A. Swabb, and Razelle Kurzrock

Acknowledgment to Reviewers

ABOUT THE COVER
Aldehyde dehydrogenase-1A1 (ALDH1A1) is heterogeneously expressed in multiple tumors. Cells with ALDH1A1 activity have been shown to have increased tumorigenicity, differentiation capacity, and chemoresistance. To confirm that the spotty heterogeneous expression of ALDH1A1 was not being visualized in tumor-infiltrating macrophages, frozen patient samples were subjected to dual immunohistochemistry against ALDH1A1 (DAB/brown) and CD68 (a pan-macrophage marker, Ferangi Blue), where distinct populations are noted. Landen and colleagues show that increased ALDH1A1 expression was associated with poor survival and is a viable target for therapy in preclinical models of ovarian cancer. For details, see article by Landen and colleagues on page 3186.
**Molecular Cancer Therapeutics**

9 (12)


| Updated version | Access the most recent version of this article at: http://mct.aacrjournals.org/content/9/12 |

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>